• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Press release

Hamlet BioPharma AB (publ): The HAMLET project featured in Cancerfonden's Christmas Campaign

Hamlet BioPharma

The Swedish Cancer Society, Cancerfonden, is a powerful and important research support organization in Sweden. Based mainly on donations, Cancerfonden and its quality review system, has ensured that cancer research has an independent, quality-based funding source. This support from Cancerfonden has allowed a diverse flora of cancer research projects to thrive and develop scientifically and in some cases clinically.

The Hamlet group at Lund University has received funding from Cancerfonden since the discovery of the HAMLET molecule and this continued support has been crucial for the scientific achievements that have been made, from discovery to the clinical studies and treatment of cancer.

This year The Christmas Campaign of Cancerfonden features the HAMLET project as an example of their success and a vehicle for the continued support through donations from the public.

We would like to draw your attention to this opportunity to support cancer research.

https://www.cancerfonden.se/stod- oss/kampanj?c_rid=60gt0q4n019ftmtSaDg- 977537727%7C148365500&utm_source=symplify&utm_medium=email&utm_campai gn=kampanjkommunikation&utm_content=edr_december2025&verifyEmailToken =false

We wish everyone Happy Holidays